Peptobiotics Secures $6.2 Million in Series A Funding
In a significant development, Peptobiotics, a startup dedicated to leveraging antimicrobial peptide technology to replace conventional antibiotic usage in aquaculture, has successfully raised $6.2 million in its series A funding round.
•
•
Do not index
Do not index
Peptobiotics, a biotechnology company dedicated to revolutionizing antibiotic usage in the aquaculture industry, proudly announces the successful conclusion of its series A funding round, securing an impressive $6.2 million.
Led by Hatch's Blue Revolution Fund, this funding will propel Peptobiotics towards the commercialization of its groundbreaking recombinant antimicrobial peptide technology. This innovation aims to replace antibiotics commonly utilized in aquaculture, addressing concerns of overuse and antimicrobial resistance.
Jonathan Bester, CEO of Peptobiotics, underscores the urgency within the aquaculture sector for non-antibiotic solutions, citing the industry's pressing disease challenges. He emphasizes the company's authentic approach tailored specifically for aquaculture, rather than adapting solutions from other agricultural domains.
Bester highlights the significance of developing cost-effective solutions, recognizing challenges faced by other agricultural biotechnology firms. Koh Jhee Hong, Chief Technology Officer, explains the breakthrough in identifying effective peptides and optimizing production for scalability and affordability.
While the timeline for commercialization remains uncertain, Peptobiotics aims to firmly establish itself and its technology in the aquaculture solutions sector, offering competitive alternatives to farmers.
Peptobiotics is proud to be part of Hatch's investment portfolio, maintaining editorial independence despite its affiliation.
Related posts
NOAA Rejects Emergency Petition to Eliminate King Salmon Bycatch Allowance in Alaska Pollock Fishery